|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM372225934 |
| 003 |
DE-627 |
| 005 |
20240615233630.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240512s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110239
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1441.xml
|
| 035 |
|
|
|a (DE-627)NLM372225934
|
| 035 |
|
|
|a (NLM)38734038
|
| 035 |
|
|
|a (PII)S1521-6616(24)00348-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bektaş, Murat
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The safety and efficacy of TNF inhibitors in patients with Behçet's disease
|b Retrospective study from eastern Turkey
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.06.2024
|
| 500 |
|
|
|a Date Revised 14.06.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a OBJECTIVE: We aimed to evaluate the clinical features, disease course, and associated factors for outcome in severe/refractory BD patients receiving TNF-i treatment
|
| 520 |
|
|
|a MATERIAL AND METHODS: This retrospective study was conducted by reviewing medical records from a tertiary referral center in Van province in Eastern Turkey. Data were obtained from patients' charts followed up between June 2019 and June 2022
|
| 520 |
|
|
|a RESULTS: We included 469 BD patients (59.3% male) whose 80 patients (17%) received TNF-i treatment in the study. The mean ± standard deviation of the patient age was 36.7 ± 10.1 years and the median (IQR) disease duration was 12 (12) years. IFX and ADAwere initiated in 67.5% (n = 54) and 32.5% (n = 26) patients, respectively. Overall and first-line retention rates of TNF-i were 84.7% and 92.6% for IFX and 83.3% and 80.8% for ADA, respectively. IFX was discontinued in 9 patients which were in 2 patients due to allergic reaction and tuberculosis, 3 patients for inefficacy, one patient for heart failure, and one patient for orbital zona. Although no serious adverse event was observed with ADA, 5 patients switched to IFX due to inefficacy. Overall, 72 patients (90%) resumed TNF-i at the end of the study; TNF-i was discontinued in 3 patients (3.8%) due to severe adverse events and in 5 patients (6.2%) with prolonged remission
|
| 520 |
|
|
|a CONCLUSION: In our study, no case of death was observed in TNF-i receiving patients. Most patients achieved attack-free and CS-free disease and retained TNF-i treatment. TNF inhibitors appear to be safe and effective in patients with severe/refractory Behçet's disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Adalimumab
|
| 650 |
|
4 |
|a Behçet's disease
|
| 650 |
|
4 |
|a Infliximab
|
| 650 |
|
4 |
|a TNF inhibitors
|
| 650 |
|
4 |
|a Vascular involvement
|
| 650 |
|
7 |
|a Adalimumab
|2 NLM
|
| 650 |
|
7 |
|a FYS6T7F842
|2 NLM
|
| 650 |
|
7 |
|a Infliximab
|2 NLM
|
| 650 |
|
7 |
|a B72HH48FLU
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Etanercept
|2 NLM
|
| 650 |
|
7 |
|a OP401G7OJC
|2 NLM
|
| 700 |
1 |
|
|a Özer, Muhammet Derda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oğuz, Emin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 264(2024) vom: 01. Juni, Seite 110239
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:264
|g year:2024
|g day:01
|g month:06
|g pages:110239
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110239
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 264
|j 2024
|b 01
|c 06
|h 110239
|